Hostname: page-component-74656f9884-skzmx Total loading time: 0 Render date: 2026-11-04T14:42:24.062Z Has data issue: false hasContentIssue false

Clinical utility of brief screening measures during neuropsychological consultation for pediatric onset multiple sclerosis

Published online by Cambridge University Press:  19 September 2024

Ashley Nguyen-Martinez*
Affiliation:
Children’s Hospital Colorado, Department of Pediatrics, Section of Child Neurology, University of Colorado, School of Medicine, Aurora, CO, USA
Brooke Weigand
Affiliation:
Children’s Hospital Colorado, Department of Pediatrics, Section of Child Neurology, University of Colorado, School of Medicine, Aurora, CO, USA
Kelly Wolfe
Affiliation:
Children’s Hospital Colorado, Department of Pediatrics, Section of Child Neurology, University of Colorado, School of Medicine, Aurora, CO, USA
Ryan Kammeyer
Affiliation:
Children’s Hospital Colorado, Department of Pediatrics, Section of Child Neurology, University of Colorado, School of Medicine, Aurora, CO, USA
Teri Schreiner
Affiliation:
Children’s Hospital Colorado, Department of Pediatrics, Section of Child Neurology, University of Colorado, School of Medicine, Aurora, CO, USA
Christa Hutaff-Lee
Affiliation:
Children’s Hospital Colorado, Department of Pediatrics, Section of Child Neurology, University of Colorado, School of Medicine, Aurora, CO, USA
*
Corresponding author: Ashley Nguyen-Martinez; Email: Ashley.Nguyen@childrenscolorado.org
Rights & Permissions [Opens in a new window]

Abstract

Objective:

Pediatric-onset multiple sclerosis (POMS) accounts for approximately 2 to 5% of all individuals with MS and is associated with an increased risk for cognitive impairment. In recent years, neuropsychological screening questionnaires have been increasingly utilized for pediatric populations in multidisciplinary settings. This study examines the clinical utility of the Colorado Learning Difficulties Questionnaire (CLDQ) and Pediatric Perceived Cognitive Functioning (Peds PCF) screening measures for identifying cognitive impairment in persons with POMS during a target neuropsychological evaluation.

Method:

Retrospective data was gathered from electronic medical records at a single pediatric hospital.

Results:

Forty-nine participants were included (69% female; 43% Hispanic/Latinx; mean age = 16.1 years old, range = 9.9 to 20.6 years old). Correlation analyses demonstrated strong interrelatedness between caregiver ratings on screening measures and performance on traditional neuropsychological measures. Effect sizes were medium across comparisons (CLDQ: Spearman’s rho = −.321 to −.563; PedsPCF: Spearman’s rho = .308 to .444). Exploratory cut-points using receiver operating characteristic analysis and Youden indices are also discussed.

Conclusions:

Comparison of scores across caregiver rating questionnaires and on a targeted neuropsychological battery suggests that the screening surveys alone may not be sensitive enough to identify children with cognitive impairments, but ratings may provide qualitatively meaningful information along with neuropsychological testing. This study illustrates how pediatric neuropsychologists can leverage screening tools to focus consultative interviews and effectively triage referrals for evaluation within an academic medical setting.

Information

Type
Research Article
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of International Neuropsychological Society
Figure 0

Table 1. Sample descriptive data (n = 49)

Figure 1

Table 2. Relationships between screening indices and neuropsychological test scores

Figure 2

Figure 1. Receiver operating characteristic curve demonstrating predictive utility of screening measures for clinical concerns on neuropsychological testing. Note: Clinical concern is defined as having 25% or more of neuropsychological test scores measuring greater than 1 standard deviation below the normative mean. PCF = Perceived Cognitive Function; CLDQ = Colorado Learning Difficulties Questionnaire. Lines in the graph represent the CLDQ, Peds PCF, or Reference lines as indicated in the legend.

Figure 3

Table 3. Sensitivity and specificity for screening measures predicting clinical concerns on neuropsychological testing